Anatomical, biochemical and physiological considerations of the colon in design and development of novel drug delivery systems

Current Drug Delivery

Volumn 9, Issue 6, 2012, Pages 556-565

  Vadlamudi, Harini Chowdary ^a   Prasanna Raju, Y ^a   Rubia Yasmeen, B ^a   Vulava, Jayasri ^a  

^a Prince Dr K Vasudevan College of Engineering and Technology   (India)

Author keywords

Luminal pressure; Lymphoid tissue; Polymers; Prodrugs; Serosa; Transit time

Indexed keywords

AZO REDUCTASE; BETA GLUCURONIDASE; CHOLECYSTOKININ A RECEPTOR; DEXTRANASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; GASTRIN RELEASING PEPTIDE RECEPTOR; GLYCOSIDASE; NEUROKININ 2 RECEPTOR; POLYGALACTURONASE; POLYMER; POLYSACCHARIDE; PRODRUG;

ARTICLE; COLON; COLON MUCOSA; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG DESIGN; ENZYME PRODRUG THERAPY; FEASIBILITY STUDY; HUMAN; HYDROGEL; INTESTINE FLORA; INTESTINE PRESSURE; INTESTINE TRANSIT TIME; LYMPH NODE; PH; PRIORITY JOURNAL; TIMED DRUG RELEASE; VASCULARIZATION;

ANIMALS; COLON; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS;

EID: 84870222109     PISSN: 15672018     EISSN: 18755704     Source Type: Journal    
DOI: 10.2174/156720112803529774     Document Type: Article

References (121)

1. Vyas, S.P.; Khar, R.K. Controlled drug delivery: concepts and advances. Vallabh Prakashan, New Delhi: 2005, pp. 218-253.
2. Chourasia, M.K.; Jain, S.K. Pharmaceutical approaches to colon targeted drug delivery systems. J. Pharm. Sci., 2003, 6, 33-66.
3. Mackay, M.; Tomlinson, E. Colonic delivery of therapeutic peptides and proteins, In: Biek PR, ed. Colonic drug absorption and metabolism. New York: Marcel Dekker, 1993, pp. 159-176.
4. Abdul, B.; John, B. Perspectives on colonic drug delivery. Business Briefing. Pharm. Tech., 2003, 185-190.
5. Sarasija, S.; Hosta, A. Colon specific drug delivery systems. Int. J. Pharm. Sci., 2000, 62, 1-8.
6. Hardy, J.G.; Wilson, C.G.; Wood, E. Drug delivery to the proximal colon. J. Pharm. Pharmacol., 1985, 37, 874-877.
7. Farthing, M.J.G.; Rutland, M.D.; Clark, M.L. Retrograde spread of hydrocortisone containing foam given intrarectally in ulcerative colitis. Br. Med. J., 1979, 2, 822-824.
8. Wood, E.; Wilson, C.G.; Hardy, J.G. The spreading of foam and solution enemas. Int. J. Pharm., 1985, 25,191-197.
9. Watts, P.; Illum, L. Colonic drug delivery. Drug Dev. Ind. Pharm., 1997, 23, 893-913.
10. Richard, L.D.; Wayne, V.; Adam, W.M.M. Gray's anatomy for students. 2005, 282-283.
11. Anne, W.; Allison, Grant. Ross and Wilson anatomy and physiology in health and illness. 9th ed., 2001, 304-306.
12. Gerard, J.T.; Bryan, Derrickson. Principles of anatomy and physiology. 11th ed, 2005, pp. 932-935.
13. Christine, Edwards. Physiology of the colorectal barrier. Adv. Drug Del. Rev., 1997, 28, 173-190.
14. BD chaurasia's human anatomy regional and applied dissection and clinical vol 2, lower limb, abdomen, pelvis. 4th ed.; CBS publishers and distributors: New delhi, 2004, pp. 252-259.
15. Ratna, J.V.; Prabhakaran, L.; Puroshotham, M. Colon targeted drug delivery system-An overview. Targ. Drug Del. Sys., 2010, 8(2), 34-39.
16. Hulten, L. Extrinsic nervous control of colonic motility and blood flow. An experimental study in the cat. Acta Physiol. Stand., 1969, 335(Suppl), 1-10.
17. Rostad, H. Colonic motility in the cat. II Extrinsic nervous control. Acta. Physiol. Scand., 1973, 89, 91-103.
18. Christensen, J.; Stiles, M.J.; Rick, G.A.; Sutherland, J. Comparative anatomy of the myenteric plexus of the distal colon in eight mammals. Gastroenterology, l984, 86, 706-713.
19. Kvietys, P.R.; Granger, D.N. Regulation of colonic blood flow. Fed. Proc., 1982, 41, 2100-2110.
20. Grandihon, A.S.; Yates, J.; Shields, R. Capillary blood flow in the canine colon and other organs at normal and raised portal pressure. Gut., 1981, 22, 273-227.
21. Fasth, S.; Hulten, L.; Lundgren, 0.; Nordgren, S. Vascular responses to mechanical stimulation of the mucosa of the cat colon. Acta. Physiol. Scand., 1977, 101, 988-1049.
22. Mortensen, F.V.; Nielsen, H.; Mulvany, M.J.; Liessov, I. Short chain fatty acids dilate isolated human colonic resistance arteries. Gut., 1990, 131, 1391-l394.
23. Kvietqs, P.R.; Granger, D.N. Effect of volatile fatty acids, on blood flow and oxygen uptake by dog colon. Gastroenterology, 1981, 80, 962-969.
24. Erik, C. Von. Rosenvinge.; Jean-Pierre, Raufman. Muscarinic receptor signaling in colon cancer. Cancers, 2011, 3,971-981.
25. Morton, F.; Harper, E.A.; Tavares, I.A.; Shankley, N.P. Pharmacological evidence for putative CCK1 receptor heterogeneity in human colon smooth muscle. Br. J. Pharmacol., 2002, 136, 873-882.
26. Nirmitha, I.H.; Andrew, W.B. The role of Eph receptors and ephrin ligands in colorectal cancer. Int. J. Cancer, 2010, 126, 2003-2011.
27. William, K.K.;. Wu.; Timothy, T. Ming, T.; Joseph, J.; Y.S.; Zhi, J. L.; Le, Y.; Chi, H.C. Expression of ErbB receptors and their Cognate ligands in gastric and colon cancer cell lines. Anticancer Research., 2009, 29, 229-234.
28. Maria, M.; Paola, G. Estrogen receptor β mediates the protective effects of estrogen in colon cancer. Cancer Ther., 2008, 6, 149-162.
29. Khong, F.Y.; Simon, C.A.; Satinder, R.; Stefan, G.H.; David, H.A. Fas/Fas ligand interaction in human colorectal hepatic metastases. A mechanism of hepatocyte destruction to facilitate local tumor invasion. Am. J. Path., 1999, 154 (3), 693-703.
30. Robert, E.C.; Denis, O.; Sean, L.; Alexey, D.; Richard, V.B. Characterization of gastrin-releasing peptide and its receptor aberrantly expressed by human colon cancer cell lines. Mol. Pharmacol., 2000, 58, 601-607.
31. Fausto, B.; Federica, U.; Francesco, R.; Dania, R.; Renato, V.; Chiara, G.; Sandra, B.; Chiara, C.; Maurizio, G.; Luigi, B.; Enio, M. growth hormone inhibits apoptosis in human colonic cancer cell lines: antagonistic effects of peroxisome proliferator activated receptor-γ ligands. Endocrinology, 2004, 145(7), 3353-3362.
32. Rioux, J.D.; Silverberg, M.S.; Daly, M.J.; Steinhart, A.H.; McLeod R.S.; Griffiths, A.M. Genomewide search in Canadian families with inflammatory bowel disease reveals two novel susceptibility loci. Am. J. Hum. Genet., 2000, 66, 1863-1870.
33. Van Heel, D.A.; Fisher, S.A.; Kirby, A.; Daly, M.J.; Rioux, J.D.; Lewis, C.M. Inflammatory bowel disease susceptibility loci defined by genome scan meta-analysis of 1952 affected relative pairs. Hum. Mol. Genet., 2004, 13, 763-770.
34. Souza, H.S.; Elia, C.C.S.; Spencer, J.; MacDonald, T.T. Expression of lymphocyte-endothelial receptor-ligand pairs, α4β7/MAdCAM-1 and OX40/OX40 ligand in the colon and jejunum of patients with inflammatory bowel disease. Gut, 1999, 45, 856-863.
35. Katharina, B.; Lei, S.; Christina, N.; Owen, M. Siggs.; S., M.; Le, Gall.; Wataru, Tomisato.; Xiaohong, L.; Xin, D.; Daniela, N. M.; Carl, P.B.; Ruce, B. MyD88 signaling in nonhematopoietic cells protects mice against induced colitis by regulating speci c EGF receptor ligands. PNAS, 2010, 107 (46), 19967-19972.
36. Sander, G.R.; Powell, B.C. Expression of notch receptors and ligands in the adult gut. J. Histochem. Cytochem., 2004, 52(4), 509-516.
37. Holly, E.M.; Marjorie, A.P.; Andrew, N.B.; Timothy, M. Willson.;Jerrold, M.W.; Kennett, J.; Frank, J. Gonzalez.; Jeffrey, M.P. Ligand activation of peroxisome proliferator-activated receptor β inhibits colon carcinogenesis. Cancer Res., 2006, 66 (8), 4394-4401.
38. Adachi, M.; Kurotani, R.; Morimura, K. PPAR γ in colonic epithelial cells protects against experimental inflammatory bowel disease. Gut., 2006, 55, 1104-1113.
39. Yun, D.; Wei-Hong, W. Peroxisome proliferator-activated receptor γ and colorectal cancer. World J. Gastrointest. Oncol., 2010, 2(3), 159-164.
40. Zhou, J.; Liu, M.; Zhai, Y.; Xie, W. The antiapoptotic role of pregnane X receptor in human colon cancer cells. Mol. Endocrinol., 2008, 22, 868-880.
41. Phrabha, S.R.; Christina, S. A.; Denis, W.; Konstantinos, K. Single-molecule binding of CD44 to fibrin versus P-selectin predicts their distinct shear-dependent interactions in cancer. J. Cell Sci., 2011, 124 (11), 1903-1910.
42. Giuliani, S.; Barbanti, G.; Turini, D.; Quartara, L.; Rovero, P.; Giachetti, A.; Maggi, C.A. NK2 tachykinin receptors and contraction of circular muscle of the human colon, characterisation of the NK2 receptor subtype. Eur. J. Pharmacol., 1991, 203, 365-370.
43. Kölbel, C.B.; Mayer, E.A.; Holtmann, G.; Layer, P.; Petschulat, W.; Erhard, J.; Goebell, H. Effects of neurokinins on human colonic motility. Neurogastroenterol. Mot., 1994, 6,119-127.
44. Croci, T.; Aureggi, G.; Manara, L.; Emonds-Alt, X.; Le Fur, G.; Maffrand, J.P.; Mukenge, S.; Ferla, G. In vitro characterisation of tachykinin NK2 receptor modulating motor responses of human colonic muscle strips. Br. J. Pharmacol., 1998, 124, 1321-1327.
45. Cao, W.; Pricolo, V.E.; Zhang, L.; Behar, J.; Biancani, P.; Kirber, M.T. Gq-linked NK2 receptors mediate neurally induced contraction of human sigmoid circular smooth muscle. Gastroenterology, 2000, 119, 51-61.
46. Koch, T.R.; Carney, J.A.; Go, V.L. Distribution and quantitation of gut neuropeptides in normal intestine and inflammatory bowel diseases. Dig. Dis. Sci., 1989, 32, 369-376.
47. Mantyh, C.R.; Gates, T.S.; Zimmerman, R.P.; Welton, M.L.; Passaro, Jr. E.P.; Vigna, S.R.; Maggio, J.E.; Kruger, L.; Mantyh, P.W. Receptor binding sites for substance P, but not substance K or neuromedin K, are expressed in high concentrations by arterioles, venules and lymph nodules in surgical specimens obtained from patients with ulcerative colitis and Crohn disease. Proc. Natl. Acad. Sci. USA., 1988, 85, 3235-3239.
48. Goldin, E.; Karmeli, F.; Selinger, Z.; Rachmilewitz, D. Colonic substance P levels are increased in ulcerative colitis and decreased in chronic severe constipation. Dig. Dis. Sci., 1989, 34,754-357.
49. 1 suppresses nonmetastatic colon cancer at an early stage of tumorigenesis. Cancer Res., 1999, 59, 3379-3386.
50. Lee, J.C.; Chow, N.H.; Wang, S.T.; Huang, S.M. Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur. J. Cancer., 2000, 36(6), 748-753.
51. Bettoun, D.J.; Buck, 2nd D.W.; Lu, J.; Khalifa, B.; Chin, W.W.; Nagpal, S. A. Vitamin D receptor-Ser/Thr phosphatase-p70 S6 kinase complex and modulation of its enzymatic activities by the ligand. J. Biol. Chem., 2002, 277, 24847-24850.
52. Evans, S.R.T.; Soldatenkov, V.; Shchepotin, E.B.; Bogrash, E.; Shechepotin, I.B. Novel 19-nor-hexafluoride vitamin D3 analog (Ro 25-6760) inhibits human colon cancer in vitro via apoptosis. Int. J. Oncol., 1999, 14, 979-985.
53. Palmer, H.G.; Gonzalez-Sancho, J.; Espada, J.; Berciano, M.T.; Puig, I.; Baulida, J.; Quintanilla, M.; Cano, A.; De Herreros, A.G.; Lafarga, M.; Munoz, A. Vitamin D3 promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of β catenin signaling. J. Cell. Biol., 2001, 154,369-387.
54. Hillier, K.; Tam, F.S.F.; Bunce, K.T.; Grossman, C. Inhibition of motility induced by the activation of 5-HT1 and 5-HT4 receptor types in isolated human colon smooth muscle. Br. J. Pharm., 1994, 112, 102.
55. McLean, P.G.; Coupar, I.M.; Molenaar, P. A comparative study of functional 5-HT4 receptors in human colon, rat oesophagus and rat ileum. Br. J. Pharm., 1995, 115, 47-56.
56. Tam, F.S.; Hillier, K.; Bunce, K.T. Characterization of the 5-hydroxytryptamine receptor type involved in inhibition of spontaneous activity of human isolated colonic circular muscle. Br. J. Pharm., 1994, 113, 143-150.
57. Tam, F.S.; Hillier, K.; Bunce, K.T.; Grossman, C. Differences in responses to 5-HT4 receptor agonists and antagonists of the 5-HT4-like receptor in human colon circular smooth muscle. Br. J. Pharm., 1995, 115, 172-176.
58. Borman, R.A.; Burleigh, D.E. Functional evidence for a 5-HT2B receptor mediating contraction of longitudinal muscle in human small intestine. Br. J. Pharm., 1995, 114, 1525-1527.
59. Makoto, K.; Kenichi, T.; Yasunori, N.; Masahiro, T.; Kaori, H.; Masaaki, T. Adenosine A1 receptor blockade reverses dysmotility induced by ischemia-reperfusion in rat colon. Eur. J. Pharmacol., 2000, 409, 319-323.
60. Yoshinaga, K.; Evers, B.M.; lzukura, M.; Parekh, D.; Uchida, T.; Townsend, C.M.JR.; Thompson, J.C. Neurotensin stimulates growth of colon cancer. Surg. Oncol., 1992, 1, 127-134.
61. Dubuc, I.; Costentin, J.; Terranova, J.P.; Barnouin, M.C.; Soubrie, P.; le Fur, G.; Rostene, W.; Kitabgi, P. The nonpeptide neurotensin antagonist, SR48692, used as a tool to reveal putative neurotensin receptor subtypes. Br. J. Pharmacol., 1994, 112, 352-354.
62. Iwase, K.; Evers, B.M.; Hellmich, M.R.; Kim, H.J.; Higashide, S.T.; Gully, D.; Townsend, Jr. C.M. Indirect inhibitory effect of a neurotensin receptor antagonist on human colon cancer (LoVo) growth. Surg. Oncol., 1996, 5, 245-251.
63. Malin, E.V.J.; Jessica, M.H.L.; Gunnar, C.H. The two mucus layers of colon are organized by the MUC2 mucin, whereas the outer layer is a legislator of host-microbial interactions. PNAS, 2010, doi: 10.1073/pnas.1006451107.
64. Miguel, Freitas.; Chantal, C. Microbial modulation of host intestinal glycosylation patterns. Microbial. Ecol. Health Dis., 2000, 2, 165-178.
65. Gendler, S.J.; Lancaster, C.A.; Taylor-Papadimitriou, J.; Duhig, T.; Peat, N.; Burchell, J.; Pemberton, L.; Lalani, E.N.; Wilson, D. Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J. Biol. Chem., 1990, 265, 15286-15293.
66. Gum, J.R.; Hicks, J.W.; Swallow, D.M.; Lagace, R.L.; Byrd, J.C.; Lamport, D.T.A.; Siddiki, B.; Kim, Y.S. Molecular cloning of cDNAs derived from a novel human intestinal mucin gene. Biochem. Biophys. Res. Commun., 1990, 171,407-415.
67. Pratt, W.S.; Crawley, S.; Hicks, J.; Ho, J.; Nash, M.; Kim, Y.S.; Gum, J.R.; Swallow, D.M. Multiple transcripts of MUC3, Evidence for two genes MUC3A and MUC3B. Biochem. Biophys. Res. Commun., 2000, 275,916-923.
68. Williams, S.J.; McGuckin, M.A.; Gotley, D.C.; Eyre, H.J.; Sutherland, G.R.; Antalis, T.M. Two novel mucin genes down-regulated in colorectal cancer identified by differential display. Cancer Res., 1999, 59, 4083-4089.
69. Moniaux, N.; Nollet, S.; Degand, P.; Laine, A.; Aubert, J.P. Complete sequence of the human mucin MUC4, a putative cell membrane-associated mucin. Biochem. J., 1999, 338, 325-333.
70. Williams, S.J.; Wreschner, D.H.; Tran, M.; Eyre, H.J.; Sutherland, G.R.; McGuckin, M.A. MUC13, a novel human cell surface mucin expressed by epithelial and hemopoietic cells. J. Biol. Chem., 2001, 276, 18327-18336.
71. Yin, B.W.T.; Lloyd, K. Molecular cloning of the CA125 ovarian cancer antigen. J. Biol. Chem., 2001, 276, 27371-27375.
72. Gum, J.R.; Crawley, S.C.; Hicks, J.W.; Szymkowski, D.E.; Kim, YS. MUC17, a novel membrane-tethered mucin. Biochem. Biophys. Res. Commun., 2002, 291,466-475.
73. Higuchi, T.; Orita, T.; Nakanishi, S.; Katsuya, K.; Watanabe, H.; Yamasaki, Y.; Waga, I.; Nanayama, T.; Yamamoto, Y.; Munger, W. Molecular cloning, genomic structure, and expression analysis of MUC20, a novel mucin protein, up-regulated in injured kidney. J. Biol. Chem., 2004, 279, 1968-1979.
74. Escande, F.; Porchet, N.; Bernigaud, A.; Petitprez, D.; Aubert, J.P.; Buisine, M.P. The mouse secreted gel-forming mucin gene cluster. Biochim. Biophys. Acta., 2004, 1676, 240-250.
75. Gum, J.R.; Hicks, J.W.; Toribara, N.W.; Rothe, E.M.; Lagace, R.E.; Kim, Y.S. The human MUC2 intestinal mucin has cysteinerich subdomains located both upstream and downstream of its central repetitive region. J. Biol. Chem., 1992, 267, 21375-21383.
76. Desseyn, J.L.; Buisine, M.P.; Porchet, N.; Aubert, J.P.; Laine, A. Genomic organization of the human mucin gene MUC5B-cDNA and genomic sequences upstream of the large central exon. J. Biol. Chem., 1998, 273, 30157-30164.
77. Li, D.Z.; Gallup, M.; Fan, N.; Szymkowski, D.E.; Basbaum, C.B. Cloning of the amino-terminal and 5'-flanking region of the human MUC5AC mucin gene and transcriptional up-regulation by bacterial exoproducts. J. Biol. Chem., 1998, 273, 6812-6820.
78. Gum, J.R.; Byrd, J.C.; Hicks, J.W.; Toribara, N.W.; Lamport, D.T.; Kim, Y.S. Molecular cloning of human intestinal mucin cDNAs. Sequence analysis and evidence for genetic polymorphism. J. Biol. Chem., 1989, 264, 6480-6487.
79. Gum, J.R.; Hicks, J.W.; Toribara, N.W.; Siddiki, B.; Kim, Y.S. Molecular cloning of human intestinal mucin (MUC2) cDNA. Identification of the amino terminus and overall sequence similarity to prepro-von Willebrand factor. J. Biol. Chem., 1994, 269, 2440-2446.
80. Sternberg, L.R.; Byrd, J.C.; Baeckstrom, D.; Hansson, G.C.; Liu, K.F.; Bresalier, R.S. Alternative splicing of the human MUC2 gene. Arch. Biochem. Biophys., 2004, 421, 21-33.
81. Lidell, M.E.; Johansson, M.E.V.; Hansson, G.C. An autocatalytic cleavage in the C-terminus of the human MUC2 mucin occurs at the low pH of the late secretory pathway. J. Biol. Chem., 2003, 278, 13944-13951.
82. Thuveson, M.; Fries, E. The low pH in trans-Golgi triggers autocatalytic cleavage of pre-alpha-inhibitor heavy chain precursor. J. Biol. Chem., 2000, 275, 30996-31000.
83. Lidell, M.E.; Moncada, D.M.; Chadee, K.; Hansson, G.C. Entamoeba histolytica cysteine proteases cleave the MUC2 mucin in its C-terminal part and dissolves the protective colonic mucus gel. Proc. Natl. Acad. Sci. U. S. A., 2006, 103, 9298-9393.
84. Velcich, A.; Yang, W.C.; Heyer, J.; Fragale, A.; Nicholas, C.; Viani, S.; Kucherlapati, R.; Lipkin, M.; Yang, K.; Augenlicht, L. Colorectal cancer in mice genetically deficient in the mucin MUC2. Science, 2002, 295, 1726-1729.
85. Van der, S.M.; De Koning, B.A.; De Bruijn, A.C.; Velcich, A.; Meijerink, J.P.; Van Goudoever, J.B.; Buller, H.A.; Dekker, J.; Van, S.I.; Renes, I.B. Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology, 2006, 131, 117-129.
86. Lievin-Le Moal, V.; Servin, A.L. The front line of enteric host defense against unwelcome intrusion of harmful microorganisms, mucins, antimicrobial peptides and microbiota. Clin. Microbiol. Rev., 2006, 19,315-37.
87. Mack, D.R.; Ahrne, S.; Hyde, L.; Wei, S.; Hollingsworth, M.A. Extracellular MUC3 mucin secretion follows adherence of Lactobacillus strains to intestinal epithelial cells in vitro. Gut, 2003, 52,827-33.
88. Barcelo, A.; Claustre, J.; Moro, F.; Chayvialle, J.A.; Cuber, J.C.; Plaisancie, P. Mucin secretion is modulated by luminal factors in the isolated vascularly perfused rat colon. Gut, 2000, 46, 218-24.
89. Smirnov, A.; Sklan, D.; Uni, Z. Mucin dynamics in the chick small intestine are altered by starvation. J. Nutr., 2004, 134, 736-42.
90. Vahouny, G.; Le, T.; Ifrim, I.; Satchithanandam, S.; Cassidy, M. Stimulation of intestinal cytokinetics and mucin turnover in rats fed wheat bran or cellulose. Am. J. Clin. Nutr., 1985, 41, 895-900.
91. Fordtran, J.S.; Locklear, T.W. Ionic constituents and osmolality of gastric and small intestinal fluids after eating. Am. J. Dig. Dis., 1966, 11(7), 503-521.
92. Evans, D.F.; Pye, G.; Bramley, R.; Clark, A.G.; Dyson, T.J.; Hardcastle, J.D. Measurement of gastrointestinal pH profles in normal ambulant human subjects. Gut, 1988, 29, 1035-1041.
93. Meldrum, S.J.; Watson, B.W.; Riddle, H.C. pH profile of gut as measured by radiotelemetry capsule. Br. Med. J., 1972, 2, 104-106.
94. Ashord, M.; Fell, J.T.; Attwood, D.; Sharma, H.; Woodhead, P. An evaluation of pectin as a carrier for drug targeting to the colon. J. Control. Rel., 1993, 26, 213-220.
95. Malagelada, J.R.; Robertson, J.S.; Brown, M.L.; Remington, M.; Duenes, J.A.; Thomforde, G.M.; Carryer, P.W. Intestinal transit of solid and liquid components of a meal in health. Gastroenterology, 1984, 87, 1255-1263.
96. Prasad, R.Y.V.; Krishnaiah, Y.S.R.; Satyanarayana, S. Trends in colonic drug delivery. A review. Ind. Drugs, 1996, 33, 1-10.
97. Coupe, A.J.; Davis, S.S.; Wilding, I.R. Variation in gastrointestinal transit of pharmaceutical dosage forms in healthy subjects. Pharm. Res., 1991, 8, 360-364.
98. Sharma, A.; Jain, K.A. Colon targeted drug delivery using different approaches. Int. J. Pharm. Stu. Res., 2010, 1(1), 60-66.
99. Vassallo, M.; Camilleri, M.; Phillip, S.F.; Brow, M.L.; Chapman, N.J.; Thomforde, G.M. Transit through the proximal colon influences stool weight in the a irritable bowel syndrome. Gastroenterology, 1992, 102, 102-108.
100. Vonderohe, M.R.; Camolleri, M.; Kvols, L.K.; Thomforde, G.M. Motor dysfunction of the small bowel and colon in patients with the carcinoid syndrome and diarrhea. New Eng. J. Med., 1993, 329, 1073-1078.
101. Diakidou, A.; Vertzoni, M.; Goumas, K.; Abrahamsson, B.; Söderlind, E.; Dressman, J.B.; Reppas, C. Characterisation of the contents of the ascending colon to which drugs are exposed after oral administration to healthy adults. Pharm. Res., 2009, 26, 2141-2151.
102. Simon, G.L.; Gorbach, S.L. Intestinal flora in health and disease. Gastroenterology, 1984, 86, 174-193.
103. Draser, B.S.; Hill, M.J. Human intestinal flora, Academic Press, (1974) London, 26.
104. Cummings, J.H.; Macfarlane, G.T. The control and consequences of bacterial fermentation in the human colon. J. Appl. Bacterial., 1991, 70, 443-459.
105. Rubunstein, A. Microbially controlled drug delivery to the colon. Biopharm. Drug Dispos., 1990, 11, 465-475.
106. Cummings, J.H.; Englyst, H.N. Fermentation in the human large intestine and available substrates. Am. J. Clin. Nutr., 1987, 45, 1243-1255.
107. Backhed, F.; Ley, R.E.; Sonnenburg, J.L.; Peterson, D.A.; Gordon, J.I. Host-Bacterial mutualism in the human intestine. Science, 2005, 307, 1915-1920.
108. Chien, Y.W. Oral drug delivery and delivery systems. In, Chien Y.W., ed. Novel drug delivery systems. New York, Marcel Dekker Inc, 1992, 139-196.
109. Scheline, R.R. Metabolism of foreign compounds by gastrointestinal microorganisms. Pharmacol. Rev., 1973, 25, 451-523.
110. Shanta, K.L.; Ravichandran, P.; Rao, K.P. Azopolymeric hydrogels for colon targeted drug delivery. Biomaterials, 1995, 16, 1313-1318.
111. Rubinstin, A.; Nakar, D.; Sintov, A. Chondroitin sulphate, A potential biodegradable carrier for colon-specific drug delivery. Int. J. Pharm., 1992, 84, 141-150.
112. Swidsinski, A.; Ladhoff, A.; Pernthaler, A.; Swidsinski, S.; Loening-Baucke, V.; Ortner, M.; Weber, J.; Hoffmann, U.; Schreiber, S.; Dietel, M. Mucosal flora in inflammatory bowel disease. Gastroenterol., 2002, 122, 44-54.
113. Sartor, R.B. Microbial influences in inflammatory bowel diseases. Gastroenterology, 2008, 134, 577-594.
114. Claudia, S. Leopold. Coated dosage forms for colon-specific drug delivery. PSTT, 1999, 2(5), 197-204.
115. Ueda, Y.; Hata, T.; Yamaguchi, H.; Ueda, S.; Kodani, M.: US4871549 (1989).
116. Gazzaniga, A.; Sangalli, M.E.; Giordano, F. Oral Chronotopic® drug delivery systems: achievement of time and/or site specificity. Eur. J. Pharm. Biopharm., 1994, 40, 246-250.
117. Watanabe, S.; Kawai, H.; Katsuma, M.; Fukui, M.: US20036506407B2 (2003).
118. Theeuwes, F.; Guittard, G.V., Wong, P.S.L: US4904474 (1990).
119. Emmanuel, O.; Akala, O.E.; Vantoria, C. Organic Redox-initiated polymerization process for the fabrication of hydrogels for colonspecific drug delivery. Drug Develop. Industrial Pharmacy, 2003, 29(4), 375-386.
120. Norihito, S.; Toshihto, T.; Masumi, V. Multiparticulate chitosan dispersed system for drug delivery. Chem. Pharm. Bull., 2003, 51 (6), 620-624.
121. Vervoort, L.; Kinget, R. In vitro degradation by colonic bacteria on inulin HP incorporated in Eudragit® RS films. Int. J. Pharm., 1996, 129, 185-190.